Inventera, a specialist company developing NANO pharmaceutical products for MRI contrast agents that is pursuing a KOSDAQ listing, set its offering price at 16,600 won.
On the 19th, Inventera said it conducted book-building for five trading days from the 11th to the 17th for institutional investors and finalized the offering price at 16,600 won, the top end of the indicated price range (band).
The company plans to raise a total of 1.18 million shares in this listing and had earlier presented, with lead manager NH Investment & Securities, an offering price band of 12,100–16,600 won.
A total of 2,309 institutions took part in the book-building, with 95.06% (2,195 cases) of all participating institutions submitting prices at or above the top of the range. The competition ratio came to 1,328.82 to 1.
Inventera, established in 2018, is a specialist in developing new MRI contrast agents. Its hallmark is a NANO structure using biocompatible iron (Fe) to enhance safety and contrast efficacy.
An NH Investment & Securities official said, "Institutional investors showed great interest in the breadth of potential indications and the scalability of Inventera's NANO-MRI contrast agent pipeline."
Meanwhile, Inventera will take subscriptions from retail investors from the 23rd to the 24th. It then plans to list on the KOSDAQ early next month. In addition to NH Investment & Securities, Eugene Investment & Securities served as co-lead manager.